Annual Cash & Cash Equivalents
$173.73 M
-$39.85 M-18.66%
December 1, 2024
Summary
- As of March 12, 2025, RARE annual cash & cash equivalents is $173.73 million, with the most recent change of -$39.85 million (-18.66%) on December 1, 2024.
- During the last 3 years, RARE annual cash & cash equivalents has fallen by -$133.85 million (-43.52%).
- RARE annual cash & cash equivalents is now -75.65% below its all-time high of $713.53 million, reached on December 31, 2020.
Performance
RARE Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$173.73 M
+$23.11 M+15.34%
December 1, 2024
Summary
- As of March 12, 2025, RARE quarterly cash and cash equivalents is $173.73 million, with the most recent change of +$23.11 million (+15.34%) on December 1, 2024.
- Over the past year, RARE quarterly cash and cash equivalents has dropped by -$39.85 million (-18.66%).
- RARE quarterly cash and cash equivalents is now -75.65% below its all-time high of $713.53 million, reached on December 31, 2020.
Performance
RARE Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
RARE Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -18.7% | -18.7% |
| 3 y3 years | -43.5% | -43.5% |
| 5 y5 years | -59.9% | -59.9% |
RARE Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -43.5% | +30.7% | -63.9% | +139.4% |
| 5 y | 5-year | -75.7% | +30.7% | -75.7% | +139.4% |
| alltime | all time | -75.7% | +2239.2% | -75.7% | +2772.0% |
Ultragenyx Pharmaceutical Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $173.73 M(-18.7%) | $173.73 M(+15.3%) |
| Sep 2024 | - | $150.62 M(-68.7%) |
| Jun 2024 | - | $480.69 M(+328.2%) |
| Mar 2024 | - | $112.25 M(-47.4%) |
| Dec 2023 | $213.58 M(+60.7%) | $213.58 M(+194.3%) |
| Sep 2023 | - | $72.58 M(-28.9%) |
| Jun 2023 | - | $102.06 M(+19.0%) |
| Mar 2023 | - | $85.77 M(-35.5%) |
| Dec 2022 | $132.94 M(-56.8%) | $132.94 M(-66.1%) |
| Sep 2022 | - | $391.65 M(+145.0%) |
| Jun 2022 | - | $159.87 M(+3.8%) |
| Mar 2022 | - | $153.99 M(-49.9%) |
| Dec 2021 | $307.58 M(-56.9%) | $307.58 M(+55.7%) |
| Sep 2021 | - | $197.54 M(-32.1%) |
| Jun 2021 | - | $290.88 M(-24.2%) |
| Mar 2021 | - | $383.79 M(-46.2%) |
| Dec 2020 | $713.53 M(+64.6%) | $713.53 M(+261.3%) |
| Sep 2020 | - | $197.49 M(-41.2%) |
| Jun 2020 | - | $335.64 M(+12.6%) |
| Mar 2020 | - | $298.19 M(-31.2%) |
| Dec 2019 | $433.58 M(+282.2%) | $433.58 M(+253.7%) |
| Sep 2019 | - | $122.58 M(-6.7%) |
| Jun 2019 | - | $131.34 M(-51.3%) |
| Mar 2019 | - | $269.71 M(+137.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2018 | $113.43 M(+12.9%) | $113.43 M(+36.7%) |
| Sep 2018 | - | $82.96 M(-25.2%) |
| Jun 2018 | - | $110.85 M(-51.1%) |
| Mar 2018 | - | $226.73 M(+125.6%) |
| Dec 2017 | $100.49 M(-37.6%) | $100.49 M(+66.4%) |
| Sep 2017 | - | $60.41 M(-33.4%) |
| Jun 2017 | - | $90.75 M(-43.1%) |
| Mar 2017 | - | $159.50 M(-1.0%) |
| Dec 2016 | $161.12 M(+72.2%) | $161.12 M(+13.2%) |
| Sep 2016 | - | $142.28 M(+158.4%) |
| Jun 2016 | - | $55.07 M(-22.2%) |
| Mar 2016 | - | $70.76 M(-24.4%) |
| Dec 2015 | $93.57 M(+284.7%) | $93.57 M(-43.9%) |
| Sep 2015 | - | $166.69 M(+218.4%) |
| Jun 2015 | - | $52.35 M(-70.6%) |
| Mar 2015 | - | $178.04 M(+632.0%) |
| Dec 2014 | $24.32 M(+227.5%) | $24.32 M(-54.4%) |
| Sep 2014 | - | $53.39 M(+205.9%) |
| Jun 2014 | - | $17.45 M(-68.5%) |
| Mar 2014 | - | $55.45 M(+646.6%) |
| Dec 2013 | $7.43 M(-91.4%) | $7.43 M(+22.8%) |
| Sep 2013 | - | $6.05 M(-93.0%) |
| Dec 2012 | $86.19 M(+709.7%) | $86.19 M |
| Dec 2011 | $10.64 M | - |
FAQ
- What is Ultragenyx Pharmaceutical annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical annual cash & cash equivalents year-on-year change?
- What is Ultragenyx Pharmaceutical quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Ultragenyx Pharmaceutical?
- What is Ultragenyx Pharmaceutical quarterly cash and cash equivalents year-on-year change?
What is Ultragenyx Pharmaceutical annual cash & cash equivalents?
The current annual cash & cash equivalents of RARE is $173.73 M
What is the all time high annual cash & cash equivalents for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high annual cash & cash equivalents is $713.53 M
What is Ultragenyx Pharmaceutical annual cash & cash equivalents year-on-year change?
Over the past year, RARE annual cash & cash equivalents has changed by -$39.85 M (-18.66%)
What is Ultragenyx Pharmaceutical quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of RARE is $173.73 M
What is the all time high quarterly cash and cash equivalents for Ultragenyx Pharmaceutical?
Ultragenyx Pharmaceutical all-time high quarterly cash and cash equivalents is $713.53 M
What is Ultragenyx Pharmaceutical quarterly cash and cash equivalents year-on-year change?
Over the past year, RARE quarterly cash and cash equivalents has changed by -$39.85 M (-18.66%)